The perimenopause is an aging transition unique to the female that leads to reproductive senescence which can be characterized by multiple neurological symptoms. To better understand potential underlying mechanisms of neurological symptoms of perimenopause, the present study determined genomic, biochemical, brain metabolic, and electrophysiological transformations that occur during this transition using a rat model recapitulating fundamental characteristics of the human perimenopause. Gene expression analyses indicated two distinct aging programs: chronological and endocrine. A critical period emerged during the endocrine transition from regular to irregular cycling characterized by decline in bioenergetic gene expression, confirmed by deficits in fluorodeoxyglucoseepositron emission tomography (FDG-PET) brain metabolism, mitochondrial function, and long-term potentiation. Bioinformatic analysis predicted insulin/insulin-like growth factor 1 and adenosine monophosphate-activated protein kinase/peroxisome proliferator-activated receptor gamma coactivator 1 alpha (AMPK/PGC1a) signaling pathways as upstream regulators. Onset of acyclicity was accompanied by a rise in genes required for fatty acid metabolism, inflammation, and mitochondrial function. Subsequent chronological aging resulted in decline of genes required for mitochondrial function and b-amyloid degradation. Emergence of glucose hypometabolism and impaired synaptic function in brain provide plausible mechanisms of neurological symptoms of perimenopause and may be predictive of later-life vulnerability to hypometabolic conditions such as Alzheimer's.
Introduction
The perimenopause, unique to the female, is a midlife transition state that precedes and leads to reproductive senescence (Brinton, 2010; Butler and Santoro, 2011) . Worldwide, there are currently >850 million women aged 40e60 years, 88% of whom will transition through the perimenopause by age 55; all women who reach the age of 60 with reproductive organs intact will transition through the perimenopause to the menopause (Brinton, 2010; Harlow et al., 2012) . This final stage is associated with a near complete decrease in ovarian secretion of estrogen and progesterone hormones (Harlow et al., 2012) . Similar to the human, rodent and nonhuman primates share common features of the perimenopausal transition, including decline in follicles, irregular cycling, irregular fertility, steroid hormone fluctuations, and insensitivity to estrogen (Brinton, 2012; Finch, 2014) .
Although the clinical definition of perimenopause focuses on functional changes in the reproductive system, the symptoms of the perimenopause are largely neurological in nature. The breadth of neurological symptoms coincident with the perimenopause is well documented in the clinical science literature (Genazzani et al., 2005; Greendale et al., 2010; Maki et al., 2008; Nelson, 2008) . These neurological symptoms including increased temperature, depression, insomnia, pain, and cognitive impairment during the perimenopausal transition are indicative of disruption in multiple systems, whereas their emergence during the same transition is indicative of a common or a set of common underlying mechanisms. Substantial evidence indicates that ovarian and neural hormones including 17b-estradiol (E2) and progesterone (P4) regulate fundamental systems in brain at both the organizational and activational levels including neurogenesis, cell survival, brain metabolism, neuroinflammation, and synaptic activity (Brinton, 2008 (Brinton, , 2009 Brinton et al., 2008; McEwen et al., 2012; Morrison et al., 2006; Rettberg et al., 2014; Simpkins et al., 2010; Woolley, 2007; Yao et al., 2011) .
The present perimenopause model builds on prior studies in middle-aged rats during their transition from regular to irregular cycling (Adams et al., 2001; Downs and Wise, 2009; Finch et al., 1984; Gore et al., 2000; Kermath and Gore, 2012) . The transition to irregular cycles was associated with cognitive impairments and altered sex steroids in hippocampus and cerebral cortex (Paris et al., 2011 ), while we found altered expression of estrogen receptor a (ERa) in astrocytes of cerebral cortex with altered neurotrophic activity in vitro (Arimoto et al., 2013) . To investigate potential underlying mechanisms of neurological dysfunction during the perimenopause, we conducted neural analyses in endocrinecharacterized rats spanning the transition from reproductively capable to reproductive senescent to aged. Using this model, we investigated the differential impact of endocrine aging versus chronological aging on hippocampal bioenergetic systems (glucose metabolism, inflammation, redox, lipid metabolism, and b-amyloid processing) and synaptic function (long-term potentiation [LTP] ). Findings from this study revealed bioenergetic transitions specific to endocrine aging during the perimenopause, that were coincident with significant decline in synaptic plasticity.
Methods

Animals
Animal studies were performed following National Institutes of Health guidelines on use of laboratory animals; protocols were approved by the University of Southern California Institutional Animal Care and Use Committee. A total of 90 young or middle-aged female Sprague-Dawley rats were obtained from Harlan Laboratories. Regular 6-month group was cycled from 5 months of age using rats that had given birth to at least 1 litter. Rats for all other groups were aged from 8-to 9-month-old retired breeders. One week after arrival, ovarian status was evaluated daily by the cytology of uterine cells obtained from lavage at 11 AM. The smear was morphologically characterized based on the 4 stages of the cycle: estrus (E), metestrus (M), diestrus (D), and proestrus (P). The regular 4-day estrus cycle is defined as the period between successive proestrus smears (P, E, M, D, P, E, M, D, P). In addition to regular cycling animals, selected groups included middleaged rodents at defined stages of perimenopause (Fig. 1B) . The irregular group was defined as 2 contiguous cycles of 5e8 days characterized by prolonged diestrus stages. The acyclic (constant estrus) group was defined as persistent vaginal cornification lasting >9 days. Rats at designated age (6 months, 9e10 months, or 16 months) and cycling status were euthanized at estrus or constant estrus. Three sets of animals were used in this study. The first set (40 rats in total) included all 5 experimental groups (regular 6 months, regular 9e10 months, irregular 9e10 months, acyclic 9e10 months, and acyclic 16 months). Of this set, N ¼ 5e6 per group were used for analyses of E2 and P4 levels, estrogen and progesterone receptors, and gene array (Figs. 1e3 and Tables 1 and 2) . A second set of rats containing only the regular 9e10 month and irregular 9e10 month groups (30 rats in total) were used for glucose tolerance test, brain glucose uptake (whole brain), protein expression (left hemisphere), and mitochondrial function (right hemisphere) analyses shown in Figs. 4 and 5. A third set of rats containing only the regular 9e10 month and irregular 9e10 month groups (20 rats in total) was used for LTP (Fig. 6) . Rats that did not meet the endocrine criteria for each group were excluded from analyses for this study.
Brain tissue collection
Rats were euthanized and the brains rapidly dissected on ice. Cerebellum and brain stem were removed from each brain and two hemispheres were separated. The cortical hemisphere was fully peeled laterally and hippocampus was then separated. Both cortex and hippocampus were harvested and frozen in À80 C for subsequent analyses.
Quantitative analysis of steroid hormones by liquid chromatography-tandem mass spectrometry (LC-MS/MS)
Levels of P4 and E2 extracted from cerebral cortex and serum were measured as previously described (Caruso et al., 2013) . 2,2,4,6,6-17a,21,21,21-D9-PROG (D9-PROG) was obtained from Medical Isotopes, (Pelham, NH, USA); 2,3,4e 13 C3-17b-estradiol ( 13 C3-17b-E) was obtained from Sigma-Aldrich. Solid phase extraction (SPE) cartridges (Discovery DS-C18 500 mg) were from Supelco, Italy. Cerebral cortex and serum were spiked with 13 C3-17b-E (1 ng/sample) and D9-PROG (0.2 ng/sample), as internal standards and homogenized in 2 mL of MeOH to acetic acid (99:1 vol/vol). After an overnight extraction at 4 C, samples were centrifuged at 12,000 rpm for 5 minutes, and the pellet was extracted twice with 1 mL of MeOH to acetic acid (99:1 vol/ vol). The organic phases were combined and evaporated to dryness. The organic residues were resuspended with 3 mL of MeOH to H 2 O (10:90 vol/vol) and passed through an SPE cartridge, previously activated with MeOH (5 mL) and MeOH:H 2 O 1:9 vol/vol (5 mL), the steroids were eluted in MeOH. Quantitative analysis was performed on the basis of calibration curves daily prepared and analyzed. Positive atmospheric pressure chemical ionization experiments were performed with a linear ion trapemass spectrometer (LTQ, ThermoElectron Co, San Jose, CA, USA) using nitrogen as sheath, auxiliary, and sweep gas. The mass spectrometer (MS) was employed in tandem mode (MS/MS) using helium as collision gas. The Hypersil GOLD column (100 Â 3 mm, 3 mm; ThermoElectron Co) was maintained at 40 C. Peaks of the LC-MS/MS were evaluated by means of the software Excalibur release 2.0 SR2. The steroids data were analyzed by analysis of variance (ANOVA) followed by pairwise comparisons. The statistical significance was indicated by p 0.05.
Low-density gene expression array
Low-density gene expression array was performed as previously described (Zhao et al., 2012) . Briefly, customerized 384-well TaqMan low-density array cards (See Supplementary Table 1 for complete list of genes) were manufactured by Invitrogen (Carlsbad, CA, USA). Total RNA was isolated from rat hippocampal tissues using the PureLink RNA Mini Kit (Invitrogen). RNA quantity and quality were analyzed before complementary DNA (cDNA) synthesis using the High Capacity RNA-to-cDNA Master Mix (Applied Biosystems). TaqMan real-time quantitative polymerase chain reactions (PCR) were performed on 50 ng cDNA samples mixed with the TaqMan Universal PCR Master 2X Mix and fluorescence was detected on an ABI 7900HT Fast Real-Time PCR System (Applied Biosystems). Data were analyzed using the RQ Manager Version (Zhao et al., 2012) .
Principal component analysis of gene expression data
As a data reduction method to obtain a summary of gene expression across a group of genes, principal component analysis (PCA) (Basilevsky, 1994) was used on groupings of gene array data. The specific gene groupings were: bioenergetics, inflammation, redox, lipid metabolism, and Alzheimer's pathology. As the transform explaining the largest degree of variance in gene expression, we extracted the first principal component (PC1) and calculated the PC1 factor scores for each animal and each gene group.
Bioinformatic analysis by Ingenuity Pathway Analysis
Expression data for genes that exhibited >5% fold change (increase or decrease) and with the p-value < 0.5 were analyzed by Ingenuity Pathway Analysis core analysis composed of a network analysis and an upstream regulator analysis. We used these relaxed criteria to maximize the coverage of the gene array results in the bioinformatic analyses. The network analysis identified biological connectivity among molecules in the data set that were upregulated or downregulated in a comparison (focus molecules that serve as "seeds" for generating networks) and their interactions with other molecules present in the Ingenuity Knowledge Base. Focus molecules were combined into networks that maximized their specific connectivity. Additional molecules from the Ingenuity Knowledge Base (interacting molecules) were used to specifically connect 2 or more smaller networks to merge them into a larger one. A network was composed of direct and indirect interactions among focus molecules and interacting molecules, with a maximum of 70 molecules per network. Generated networks were ranked by the network score according to their degree of relevance to the network eligible molecules from the data set. The network score was calculated with Fisher's exact test, taking into account the number of network eligible molecules in the network and the size of the network, as well as the total number of network eligible molecules analyzed and the total number of molecules in the Ingenuity Knowledge Base that were included in the network. Higher network scores are associated with lower probability of finding the observed number of network eligible molecules in a given network by chance.
The Ingenuity's Upstream Regulator Analysis in Ingenuity Pathway Analysis is a tool that predicts upstream regulators from gene expression data based on the literature and compiled in the Ingenuity Knowledge Base. A Fisher's exact test p-value was calculated to assess the significance of enrichment of the gene expression data for the genes downstream of an upstream regulator. A z-score was given to indicate the degree of consistent agreement or disagreement of the actual versus the expected direction of change among the downstream gene targets. A prediction about the state of the upstream regulator, either activated or inhibited, was made based on the z-score.
Brain glucose uptake
Brain glucose uptake (2-deoxy-2-[fluorine-18]fluoro-D-glucose [ 18 FDG]-microPET/microCT) was determined as previously described (Ding et al., 2013) . Briefly, rats (n ¼ 10e12 per group) were maintained under anesthesia during microPET and microCT scans with 2%e2.5% isoflurane in oxygen. Scans were performed in an imaging chamber equipped with a nose cone for anesthesia delivery and heating pad for body temperature control as previously described. MicroPET imaging was performed with a microPET R4 rodent model scanner (Concorde Microsystems Inc, Knoxville, TN, USA) and microCT imaging was performed on MicroCAT II tomography (Siemens Preclinical Solutions, Knoxville, TN. USA). Rats were injected intravenously via the tail vein with radiotracer [ 18 F] FDG (400 mCi, 100 mL). Radioactive dose was determined before injection by radioisotope dose calibrator (Capintec, CRC-712M). At 40 minutes post injection of FDG, each rat was positioned in the microPET scanner in the center of the 10.8-cm transaxial and 8-cm axial field of view. Brain microPET data were collected for 10 minutes followed by a 10-minute microCT scan for the purpose of coregistration. Coregistration of microPET and microCT data was performed using the AMIDE software package (http://amide.sourceforge.net/). After coregistration of the PET and CT images, region of interest was defined and used to measure the radioactivity concentration in brains. Decay correction was used to adjust the actual radioactivity dosage injected (Actual radioactivity dosage at time of injection ¼initial radioactivity Â e Àln 2Â T 110 , T ¼ minutes between injected time point and initial time point). Data were analyzed using Student t test.
Glucose tolerance test
Rats were fasted overnight and micro-volume blood samples were collected by puncturing tail vein. Baseline blood glucose level was measured before injection with D-glucose (2 g/kg, intraperitoneally). After glucose injection, micro-volume blood samples were collected at 5, 15, 30, 60, 90, and 120 minutes and glucose levels were determined using a glucometer (Abbott Diabetes Care, Alameda, CA, USA). The area under the curve for each group based on their averaged glucose levels at different time points was calculated.
Protein expression analysis
Rats were euthanized and the brains were rapidly dissected on ice. Hippocampal tissue was processed for protein extraction using Tissue Protein Extraction Reagent (Thermo Scientific, Rockford, IL, USA) with phosphatase and protease inhibitors (Sigma, St. Louis, MO, USA). Protein concentrations were determined with the Bio-Rad Bradford assay. Equal amounts of protein (20 mg/well) were loaded to SDS PAGE Criterion gel (Bio-Rad, Hercules, CA, USA) and electrophoresed with Tris/glycine running buffer (pH 8.3). Proteins were transferred to 0.45-mm pore size polyvinylidene difluoride membranes and probed with primary antibodies against glucose transporter 3 (GLUT3), pyruvate dehydrogenase E1a subunit (PDHE1a), estrogen receptor b (ERb) (Abcam, Cambridge, MA, USA), and estrogen receptor a (ERa) and ATP synthase F1 complex assembly factor 2 (Atpaf2) (Proteintech, Chicago, IL, USA). All other primary antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA). Horseradish peroxidase-conjugated anti-rabbit antibody and horseradish peroxidase-conjugated anti-mouse antibody (Vector Laboratories, Burlingame, CA, USA) were used as secondary antibodies. Immunoreactive bands were visualized with Pierce SuperSignal Chemiluminescent Substrates (Thermo Scientific, Waltham, MA, USA) and captured by Molecular Imager ChemiDoc XRS System (Bio-Rad Laboratories). All band intensities were quantified using the Un-Scan-It (version 6.0, Silk Scientific, Orem, UT, USA) software and normalized to the expression of b-actin.
Brain mitochondria isolation
Rats were euthanized and the brains were rapidly dissected on ice. Cerebellum and brain stem were excluded for mitochondrial isolation. Whole-brain mitochondria were isolated as previously described (Lam et al., 2009; Yao et al., 2009) . Briefly, the brain was rapidly minced and homogenized at 4 C in mitochondrial isolation buffer (MIB) (pH 7.4), containing sucrose (320 mM), EDTA (1 mM), Tris-HCl (10 mM), and Calbiochem's Protease Inhibitor Cocktail Set I (4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride 500 mM, aprotonin 150 nM, E-64 1 mM, EDTA disodium 500 mM, leupeptin hemisulfate 1 mM). Single-brain homogenates were then centrifuged at 1500g for 5 minutes. The pellet was resuspended in MIB, rehomogenized, and centrifuged again at 1500g for 5 minutes. The postnuclear supernatants from both centrifugations were combined, and crude mitochondria were pelleted by centrifugation at 21,000g for 10 minutes. The resulting mitochondrial pellet was resuspended in 15% Percoll made in MIB, layered over a preformed 23% per 40% Percoll discontinuous gradient, and centrifuged 31,000g for 10 minutes. The purified mitochondria were collected at the 23% per 40% interface and washed with 10-mL MIB by centrifugation at 16,700g for 13 minutes. The loose pellet was collected and transferred to a microcentrifuge tube and washed in MIB by centrifugation at 9000g for 8 minutes. The resulting mitochondrial pellet was resuspended in MIB to an approximate concentration of 1 mg/mL. The resulting mitochondrial samples were used immediately for respiratory measurements and hydrogen peroxide production. During mitochondrial purification, aliquots were collected for confirmation of mitochondrial purity and integrity following a previously established protocol (Irwin et al., 2008) .
Mitochondrial respiration
Mitochondrial respiration was measured using the Seahorse XF-96 metabolic analyzer following established protocol (Rogers et al., 2011) . Briefly, purified mitochondria were determined for protein concentration and resuspended into 1X mitochondrial assay (MAS) solution (70 mM sucrose, 220 mM mannitol, 10 mM KH 2 PO 4 , 5 mM MgCl 2 , 2 mM (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 1 mM ethylene glycol tetraacetic acid, and 0.5% [wt/vol] fatty acid free bovine serum albumin, pH 7.2 at 37 C) 4 mg of mitochondrial samples in 25 mL 1X MAS buffer were seeded into each assay well. Mitochondrial samples were spun down at 2000g for 10 minutes and then supplemented with 75 mL 1X MAS buffer with substrate (glutamate/malate 5 mM). Metabolic flux cartridges were loaded with the following reagents in 1X MAS: port A: adenosine diphosphate (ADP) (20 mM); port B: oligomycin (30 mg/ mL); port C: FCCP (carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone) (28 mM); and port D: rotenone (16 mM) þ antimycin (70 mM). Injection volumes for all ports were 25 mL. Mitochondrial respiration was measured sequentially in a coupled state with substrate present (basal respiration, state 4 respiration), followed by ADP-stimulated state 3 respiration after port A injection, (phosphorylating respiration in the presence of ADP and substrates). Injection of oligomycin in port B induced state 4 0 respiration and the subsequent injection of FCCP in port C induced uncoupler-stimulated respiration state 3u while the final injection of rotenone and antimycin in port D resulted in nonoxidative phosphorylationerelated residual oxygen consumption OCR residual . Respiratory control ratio value was calculated as the ratio of oxygen consumption rate (OCR) at state 3 respiration over OCR at state 4 respiration: respiratory control ratio ¼ OCR state3 /OCR state4.
H 2 O 2 production assay
The rate of hydrogen peroxide production by freshly isolated mitochondria (20 mg) was determined by the Amplex Red Hydrogen Peroxide/Peroxidase Assay kit (Invitrogen) as previously described (Yin et al., 2012) with the presence of 5-mM glutamate/malate but not ADP (state 4).
Enzyme activity assays
Complex I, complex IV, and adenosine triphosphate (ATP) synthase activity were assessed in isolated mitochondria (20 mg) using Rapid Microplate Assay kit for rat complex I, complex IV, and ATP synthase activity, respectively (MitoSciences, Eugene, OR, USA) following the manufacturer's instructions.
LTP and input and/or output curves
Input/output (I/O) responses and LTP of hippocampal region was determined electrophysiologically as previously described (Sancheti et al., 2013) . Briefly, each animal was decapitated after deep isoflurane anesthesia and slices processed in sucrosemodified artificial cerebrospinal fluid containing: 105 mM sucrose; 62 mM NaCl, 3 mM KCl, 4 mM MgCl 2 , 1.25 mM NaH 2 PO 4 , 26 mM NaHCO 3 , and 10 mM glucose. Field excitatory postsynaptic potentials (fEPSPs) were recorded from stratum radiatum of CA1 using a glass pipette filled with 2M NaCl (yielding a resistance of 2e3 MU) in response to orthodromic stimulation (twisted nichrome wires, 50 mm) of the Schaffer collateral-commissural projections in CA1 stratum radiatum. Pulses of 0.1 ms duration were delivered to the stimulating electrode every 20 seconds. The responses were amplified with Axoclamp 2A DC amplifier (Axon Instruments, Foster City, CA, USA), filtered at 6 kHz, and digitized at 20 kHz. Data acquisition was controlled by Clampex 9.0 software. I/ O curves were generated using stimulus intensities from 100 to 350 mA in increments of 50 mA. Baseline fEPSP were evoked at 30%e50% of maximal fEPSP in 20-second intervals. LTP was induced at baseline intensity using theta burst stimulation (TBS) consisting of 10 trains of 5-pulse 100 Hz stimulation repeated at 5 Hz. Recording continued for at least 30 minutes after TBS. fEPSP slope magnitude was calculated as the difference between 2 cursors, separated by 1 ms, and placed on the middle portion of the ascending phase of the fEPSP. Three consecutive responses separated with 20-second intervals were averaged and presented as a single point to reduce deviations. LTP were expressed as a percentage of the average slope from the baseline recordings. Comparison of theta burst-induced plasticity was performed between groups using repeated measures ANOVA (across all post-theta burst time points). This analysis was followed by a post hoc t test performed between groups for the average change in fEPSP amplitude recorded during the final 5 minutes of recording (30 minutes post TBS).
Results
The perimenopause animal model
Nine-to 10-month-old female Sprague-Dawley rats were stratified into groups according to the stage of ovarian senescence that followed the classification of the human perimenopausemenopause transition as per Stages of Reproductive Aging Workshop (STRAW) (Finch, 2014; Harlow et al., 2012) . The endocrine aging groups included regular cyclers (4e5 day cycles), irregular cyclers (5e8 day cycles), and acyclic (no cycling within 9 days) at 9e10 months. Six-month-old regular cycling rats and 16-month-old acyclic rats were included to distinguish endocrine aging from chronological aging (Brinton, 2013) (Fig. 1A) . From 6 months to 9e10 months, rats exhibited the greatest breadth of endocrine aging phenotypes (Fig. 1B) : at 6 months, 82% of females were regular cyclers and 18% were irregular cyclers; at 8e9 months, 60% were regular cyclers and the percentage of irregular cyclers doubled to 37%, with the first appearance of acyclicity in 3%; at 9e10 months, the percent of regular cyclers declined to 38%, the percent of irregular cyclers increased to 50%, and the remaining 12% were acyclic; at 16 months, all rats were acyclic. Increase in body weight was observed between the 6-month-old and the 9-to 10-month-old regular cyclers (p ¼ 0.023) and was constant for all subsequent stages (Fig. 1C ). There were no differences in body weight among 9-to 10-month-old animals at different endocrine stages (p ¼ 0.33). Uterine weight did not differ across the 5 endocrine phenotypes (p ¼ 0.69) and was consistent with all animals being euthanized at estrus or constant estrus (Fig. 1C) .
E2 and P4 levels were quantified by LC-MS/MS in serum and cerebral cortex collected at estrus across all groups. The pattern of serum and cortical levels of E2 across all groups differed inasmuch as serum E2 was not correlated with cortex E2 at the same endocrine stage (Fig. 2AeC) . Although serum E2 levels were highest in the 9-to 10-month-old regular and irregular cyclers and declined thereafter ( Fig. 2A) , the most robust E2 change was a collapse in cortex levels from 6 months to 9-to 10-month-old rats with negligible brain E2 observed in acyclic rats (Fig. 2B) . In contrast to E2, serum P4 levels were correlated with cortical levels (Fig. 2F ). In serum, P4 level was greatest in the 9-to 10-month-old irregular cyclers and declined significantly with the transition into 9-to 10-month-old acyclic, and remained low in the 16-month acyclic group (Fig. 2D ). In cortex, there was a trend toward decreased P4 level from 6 months regular to 9-to 10-month-old regular and irregular cyclers, which was statistically significant when animals transitioned into acyclicity at the same age (Fig. 2E) .
The impact of chronological and endocrine aging on ovarian hormone receptors in hippocampus was assessed by the protein expressions of the ERa and ERb in the hippocampus, the progesterone receptors A (PR-A) and B (PR-B), and the progesterone receptor membrane component 1 (Brinton, 2009; Brinton et al., 2008; Singh et al., 2013) . ERa expression was unaffected by either chronological or endocrine aging (Fig. 2G , p ¼ 0.22). Conversely, ERb expression declined in the 9-to 10-month-old irregular cyclers (p ¼ 0.05) and rebounded with the onset of acyclicity at the same age (p ¼ 0.004) (Fig. 2H ). Compared with 6-month-old regular cyclers, the 9-to 10-month-old irregular cyclers had an increased expression of both PR-A (Fig. 2I , p ¼ 0.001) and PR-B (Fig. 2J , p < 0.001). The major difference in PR-A expression was between the 6-monthold and 9-to 10-month-old regular cyclers (p < 0.001) whereas that in PR-B expression was between the 9-month-old regular and irregular cyclers (p ¼ 0.04) (Fig. 2I and J) . The expression of progesterone receptor membrane component 1 did not change across groups (Fig. 2K , p ¼ 0.83).
Bioenergetics-, inflammation-and Alzheimer's pathologyerelated gene expression in the hippocampus
Gene expression profiles in the hippocampus derived from the perimenopause animal model (PAM) rats were determined with emphasis on energy metabolism, inflammation, and Alzheimer's disease (AD) pathology. The AD pathologyerelated gene group is a panel related to brain aging and AD that emphasizes targets and pathways implicated in estrogen-mediated protection. Conceptually, estrogen protects the brain against AD in part by (1) reducing b-amyloid production and enhancing its clearance, (2) protecting against apoptosis, and (3) supporting neuronal function and signaling. This panel assesses these 3 established estrogen actions. Differences in gene expression were analyzed by ANOVA followed by pairwise t tests for each transition period. Heatmaps of gene expression clustered by their function were generated (Fig. 3A ) and significant differences are summarized in Table 1 
Three sets of comparisons of the gene expression profiles were conducted to distinguish age-related versus endocrine-related changes:
(1) Comparison between 6-month-old and 9-to 10-month-old regular cyclersdthis comparison represents the effect of chronological aging before the perimenopausal transition (Fig. 3A , Table 1 ). The 9-to 10-month-old regular cyclers showed a significant decline in the expression of genes involved in molecule transport (heat shock 60 kDa protein 1 and B-cell lymphoma 2/adenovirus E1B interacting protein 1); mitochondrial redox enzymes glutaredoxin 2 and peroxiredoxin 3; the glutamate decarboxylases (which generate the neurotransmitter g-aminobutyric acid), and a neuronal survival gene (chemokine receptor Cxrcr4) (Table 1) . Genes significantly upregulated included those involved in redox-sensitive transcription (nuclear factor erythroid 2-like 2), lipid metabolism (hydroxyacyl-CoA dehydrogenase, phospholipases C gamma 2, and D1), cholesterol homeostasis and trafficking (apolipoprotein A1 and ATP-binding cassette sub-family A member 7), inflammation (complement component 4A), amyloid processing (N-acylaminoacyl-peptide hydrolase), and apoptosis (caspase 8 and clusterin) ( Table 1) . Consistent with these significant differences, functional group analyses (Fig. 3A) indicated a trend toward decline in genes involved in substrate transport, tricarboxylic acid cycle, electron transfer chain, and mitochondrial biogenesis/dynamics and an increase in genes involved in inflammation, apoptosis, and cholesterol homeostasis. (2) Comparison among endocrine status groups in 9-to 10-monthold ratsdcomparisons among 9-to 10-month-old regular cyclers, irregular cyclers, and acyclic animals represent the impact of endocrine status independent of chronological age. Compared with regular cyclers, the irregular cyclers exhibited a significant decline in the expression of genes involved in bioenergetics (Atpaf2 and estrogen-related receptor alpha [a regulator of mitochondrial biogenesis]), lipid metabolism (phospholipase C, beta 3), inflammation (interleukin 1 receptor-like 1), the downstream Mapk3 (Erk1) and nuclear factor of kappa light polypeptide gene enhancer in B-Cells 2 [Nfkb2]), and amyloid processing (thimet oligopeptidase and microtubule-associated protein 2) ( Table 1) . Compared with the 9-to 10-month-old irregular cyclers, the acyclic animals exhibited higher expression of genes involved in fatty acid uptake by the mitochondria (carnitine palmitoyltransferase 2 and phospholipase A2 group 2A), mitochondrial biogenesis and ATP generation (Atpaf2 and estrogen-related receptor b), inflammation (C-X-C motif chemokine 12, Cd40, tumor necrosis factor alphaeinduced protein 2 [Tnfaip2]), cholesterol homeostasis (apolipoprotein A1 and steroidogenic acute regulatory protein), and amyloid and apoptosis related (Apba3 and Bcl2l1) ( Table 1 ). The expression of amyloid precursor proteinbinding, family B, member 1, decreased in acyclic animals (Table 1) . Functional group analyses revealed a decline in irregular cyclers relative to regular cyclers in genes involved in glucose transport, glycolysis, mitochondrial energytransducing systems (tricarboxylic acid cycle, electron transfer chain, oxidative phosphorylation, mitochondrial biogenesis, and mitochondrial dynamics), cellular redox homeostasis, inflammation (adhesion, chemokines, interleukins, phospholipases), Ab clearance and degradation, apoptosis, and synaptic plasticity (Fig. 3A) . Functional group analyses between the 9-to 10-month-old irregular cyclers and acyclic animals revealed that the deficits in glycolytic genes persisted into the acyclic condition. In contrast, mitochondrial genes were increased with the transition into acyclicity and those involved in synaptic plasticity were partially recovered (Fig. 3A) . (3) Comparison between 9-to 10-month-old acyclic and 16-month-old acyclic groupsdThis transition primarily reflects the impact of chronological aging on gene expression profiles.
Compared with the 9-to 10-month-old acyclic group, the 16-month-old acyclic group exhibited lower expression of genes involved in bioenergetics (translocase of inner mitochondrial membrane 23 homolog, pyruvate dehydrogenase phosphatase catalytic subunit 1, nicotinamide adenine dinucleotide dehydrogenase [ubiquinone] iron-sulfur protein 4 and 8, cytochrome oxidase subunit IV isoform 2, and Atpaf2), lipid metabolism (phospholipase A2 group 1B [Pla2g1b] and peroxisome proliferator-activated receptor gamma), amyloid processing (Apba3, and insulin-degrading enzyme [Ide]), apoptosis (Bcl2l1) ( Table 1 ). In contrast, the glycolytic gene phosphofructokinase 1 and the cell signaling gene Erk1 were significantly increased in the 16-month-old acyclic group (Table 1) . Functional group analyses indicated downregulation of genes involved in glucose metabolism, mitochondrial biogenesis, and dynamics, Ab clearance and degradation, and apoptosis (Fig. 3A) .
Changes in gene expression patterns across all age and endocrine states were quantified by PCA for the 5 major functional gene groups; the PC1 scores of individual animals were calculated for each gene group. The bioenergetic gene group (encompassing glucose metabolism and mitochondrial function) was the only gene group that showed a significant difference in PC1 score across the 5 animal groups (Fig. 3B , F ¼ 5.04, p < 0.01). The other gene groups (redox, inflammation, lipid metabolism, and AD) did not show statistically significant differences across groups (data not shown). Pairwise comparison of the PC1 scores of bioenergetic genes showed a significant decline from 6-month-old regular cyclers to 9-to 10-month-old irregular cyclers and from the 9-to 10-month-old acyclic to 16-month-old acyclic. The 9-to 10-month-old acyclic group showed a significant increase in bioenergetic PC1 scores compared with the 9-to 10-month-old irregular cyclers (Fig. 3B) . Moreover, the changes in bioenergetic gene expression profile were independent of other functional group (i.e., redox-, inflammation-, lipid metabolism-, and AD pathologyerelated genes), at the transcription level (Fig. 3C) . In contrast, changes in redox-, inflammation-and lipid metabolismerelated genes were tightly correlated with each other, indicating that these 3 functional groups may either be under a common regulatory pathway or share a common intermediating pathway. The changes in AD pathologyerelated genes were correlated with the inflammatory gene group, indicating that prolonged inflammation may contribute to the AD pathogenic pathway (Fig. 3C) .
Network and pathway analyses identified gene nodes and upstream regulators
Hippocampal gene expression data were further analyzed by the Ingenuity Pathway Analysis to identify networks of genes and their upstream regulators (Table 2 ). The network analysis revealed known interactions among the genes in the data set and predicted interactions from the knowledge base and identified nodes within the network. Analyses for upstream regulators identified transcriptional networks predictive of the observed patterns of gene expression.
The network analysis of bioenergetic genes identified key nodes that unified gene changes across both chronological and endocrine aging including insulin, insulin-like growth factor 1, insulin receptor substrate-1 (IRS-1), phosphoinositide 3-kinase (PI3K), protein kinase B (Akt), cAMP response element-binding protein (CREB), c-Jun N-terminal kinase (JNK), extracellular signal-regulated kinase 1/2 (ERK1/2), 5 0 adenosine monophosphate-activated protein kinase (AMPK), NFkB, and cluster of differentiation 3 (CD3). Analyses of predictive upstream regulators indicated that differences in gene expression patterns during chronological and endocrine aging was primarily related to the insulin/IGF-1-IRS-PI3K/Akt-ERK signaling pathway and the AMPK-PGC1a-nuclear respiratory factor-1 transcriptional pathway (Table 2) . Insulin/IGF1 signaling is primarily Genes that showed statistically significant changes (p ¼ 0.001e0.05) are grouped based on their primary function for each transition period. Results were based on pairwise comparisons of the gene expression, either upregulated or downregulated. Key: Abca7, ATP-binding cassette sub-family A member7; Apba3, amyloid beta A4 precursor protein-binding family A member 3; Apeh, N-acylaminoacyl-peptide hydrolase; Apbb1, APP-binding, family B, member 1; Apoa1, apolipoprotein A1; Atpaf2, ATP synthase F1 complex assembly factor 2; Bcl2l1, BCL2-Like 1; Bnip1, Bcl2/ adenovirus E1B interacting protein 1; C4a, complement component 4A; Casp8, caspase 8; Cd40, cluster of differentiation 40; Clu, clusterin; Cox4i2, cytochrome oxidase subunit IV isoform 2; Cpt2, carnitine palmitoyltransferase 2; Cxcl12, C-X-C motif chemokine 12; Cxcr4, C-X-C chemokine receptor type 4; Esrrb, estrogenrelated receptor b; Gad1, glutamate decarboxylase 1; Gad2, glutamate decarboxylase 2; Hadh, hydroxyacyl-CoA dehydrogenase; Grx2, glutaredoxin 2; Hrh1, histamine receptor H1; Hspd1, heat shock 60 kDa protein 1; Ide, insulin-degrading enzyme; Il1rl1, interleukin 1 receptor-like 1; Map2, microtubule-associated protein 2; Mapk3, microtubule-associated protein 3; Ndufs4, nicotinamide adenine dinucleotide dehydrogenase [ubiquinone] iron-sulfur protein 4; Ndufs8, nicotinamide adenine dinucleotide dehydrogenase [ubiquinone] iron-sulfur protein 8; Nfe2l2, nuclear factor erythroid 2-like 2; Nfkb2, nuclear factor of kappa light polypeptide gene enhancer in B-cells 2; Pdp1, pyruvate dehydrogenase phosphatase catalytic subunit 1; Pfk1, phosphofructokinase 1; Plcb3, phospholipase C, beta 3; Pla2g1b, phospholipase A2 group 1B; Pla2g2a, phospholipase A2 group 2A; Plcg2, phospholipases C gamma 2; Pparg, peroxisome proliferator-activated receptor gamma; Prx3, peroxiredoxin 3; Star, steroidogenic acute regulatory protein; Thop1, thimet oligopeptidase; Timm23, translocase of inner mitochondrial membrane 23 homolog; Tnfaip2, tumor necrosis factor alphaeinduced protein 2. 0 adenosine monophosphate-activated protein kinase; AP1, activator protein 1; Bad, Bcl-2-associated death promoter; Bax, Bcl-2-associated X protein; Bcl2, B-cell lymphoma 2; BclXL, B-cell lymphoma-extra large; Casp8, caspase 8; CD3, cluster of differentiation 3; CD40, cluster of differentiation 40; Creb, cAMP response element-binding protein; Cytc, cytochrome complex; ERK1/2, extracellular signal-regulated kinase 1/2; ESRRA, estrogen-related receptor alpha; ICAM1, intercellular adhesion molecule 1; IFNg, interferon gamma; IGF-1, insulin-like growth factor 1; IGF1R, insulin-like growth factor-1 receptor; IL1, interleukin 1; IL1B, interleukin-1 beta; IL6, interleukin 6; IL12, interleukin 12; INSR, insulin receptor; IPA; Ingenuity Pathway Analysis; IRS1, insulin receptor substrate-1; JNK, c-Jun N-terminal kinase; MEK, mitogenactivated protein kinase kinase; Myc, avian myelocytomatosis viral oncogene homolog; NFE2L2, nuclear factor erythroid 2-like 2; NFkB, nuclear factor of kappa light polypeptide gene enhancer in B-cells; NRF1, nuclear respiratory factor-1; NR4A3, nuclear receptor subfamily 4, group A, member 3; PI3K, phosphoinositide 3-kinase; PI3K/Akt, phosphoinositide 3-kinase/protein kinase B; PPARA, peroxisome proliferator-activated receptor alpha; Pparg, peroxisome proliferator-activated receptor gamma; PPARGC1A, peroxisome proliferator-activated receptor gamma coactivator 1 alpha; TLR, toll-like receptor; PTEN, phosphatase and tensin homolog; TNF, tumor necrosis factor; TP53, tumor protein p53.
involved in regulation of bioenergetic functions whereas the AMPKPGC1a pathway senses energy needs and drives mitochondrial biogenesis.
Key nodes within the inflammatory network include IL1, IL12, CD40, ERK1/2, and toll-like receptors and upstream regulator analyses indicated that differences in patterns of inflammatory gene expression could be ascribed to the IL1/tumor necrosis factor-MAPK-NFkB pathway (Table 2 ). Key nodes of the Alzheimer'srelated genes included ERK1/2, mitogen-activated protein kinase kinase, CREB, IL1, activator protein 1, B-cell lymphoma 2, B-cell lymphoma-extra large, Bcl-2-associated X protein, Bcl-2-associated death promoter, caspase 8, and cytochrome complex. Upstream regulator analyses indicated that differences in Alzheimer's-related gene expression patterns could be attributed to the IGF1-PI3K/Akt-ERK1/2 signaling pathway and the NFkB pathway (Table 2) .
3.4. Decline in bioenergetic enzyme expression was accompanied by inhibition of the insulin/IGF1 and AMPK signaling pathways in hippocampus during the regular-irregular transition Gene expression analyses indicated that changes in the brain bioenergetic profile were among the earliest indicators associated with the perimenopausal transition in the hippocampus; these changes were prominently represented by the difference between 9-to 10-month-old regular and irregular cyclers. The endocrine transition state manifested by irregular cycling thus emerged as a critical period for bioenergetic function. We, therefore, further characterized the irregular cycling group regarding their bioenergetic and synaptic function using regular cycling rats of the same age as the reference group. Consistent with the gene array data, the expression of glucose transporter 3 (GLUT3, p ¼ 0.03), pyruvate dehydrogenase E1a subunit (p ¼ 0.03), and Atpaf2 (p ¼ 0.04) were decreased in the hippocampus of irregular cyclers (Fig. 4AeC) . Cytosolic signaling components and transcriptional pathways identified by bioinformatic analyses were assessed in the hippocampus, with results shown in Fig. 4DeJ . The insulin/IGF1 signaling cascade from IRS-1 (Fig. 4D ; p-IRS1 Tyr608 /IRS1, p < 0.001), to Akt ( Fig. 4E ; p-Akt/Akt, p ¼ 0.02), and ERK1/2 ( Fig. 4F ; p-ERK1, p ¼ 0.009; p-ERK2, p ¼ 0.03) were substantially decreased in the irregular cyclers; this pattern was accompanied by the decline in transcriptional pathways CREB ( Fig. 4G ; p-CREB, p ¼ 0.005) and AMPK ( Fig. 4H ; p-AMPK, p < 0.001). The expression of PGC1a did not differ between regular and irregular cycling groups (data not shown). The expression and activation of the master regulator of cellular inflammatory responses, NFkB, was also decreased in the irregular cyclers (Fig. 4I , NFkB, p ¼ 0.02; Fig. 4J , p-IkB/IkB, p ¼ 0.04).
Brain metabolism declines during regular-irregular transition
18 Eighteen-FDG-microPET coregistered with microCT imaging revealed a 15% decrease in whole-brain glucose uptake in the 9-to 10-month-old irregular cyclers relative to regular cyclers ( Fig. 5A and B, p ¼ 0.03); this decrease correlated with a decrease in systemic glucose tolerance (Fig. 5C , p ¼ 0.01 for area under the curve). The glucose-metabolizing machinery in the whole brain (not including cerebellum and brain stem) of 9-to 10-month-old irregular cyclers was also substantially diminished in terms of mitochondrial respiratory control ratios (Fig. 5D , p ¼ 0.04) and the activities of mitochondrial complexes IV (Fig. 5E , p ¼ 0.03) and V (Fig. 5F , p ¼ 0.03). Activity of the mitochondrial complex I remained unchanged (data not shown). These metabolic changes were accompanied by a substantial increase in mitochondrial H 2 O 2 production (Fig. 5G , p ¼ 0.03), thus substantiating a compromised mitochondrial energy-redox axis (Yin et al., 2014) .
Decline of synaptic plasticity in irregular cyclers
Deficits in bioenergetic gene and protein expression, brain metabolism, mitochondrial function, and the inactivation of ERK pathway are expected to lead to a decline in synaptic transmission. LTP observed in the hippocampal CA1 region has been considered critical for learning and memory. Analysis of I/O responses in the CA1 region indicated that the machinery required for synaptic transmission remained intact as there was no difference in the I/O curves between the regular and irregular cyclers (Fig. 6A, p ¼ 0.13) . In contrast, LTP in the CA1 region of irregular cyclers was significantly lower than that of regular cyclers: responses after high frequency stimulation (relative to baseline) were lower in the irregular cyclers (Fig. 6B ) (F ¼ 366.2, p < 0.001); the LTP magnitude of regular cyclers was 180.6% EPSP, whereas that of the irregular cyclers was 168.2% EPSP (Fig. 6C , p ¼ 0.007). These data indicate that the machinery necessary to establish synaptic potentials is functional in both regular and irregular cyclers; however, the ability to sustain high-frequency synaptic activity was significantly compromised in the irregular cyclers consistent with their deficits in bioenergetic gene expression profile (Fig. 3B) , decreased glucose uptake (Fig. 5A,B) , and mitochondrial energy-conservation systems and their regulators (Figs. 4 and 5 ).
Discussion
Findings from this investigation support the PAM model as a physiologically-relevant rodent model of human perimenopause and provide mechanistic insights regarding the transitions within bioenergetic systems inherent in chronological and endocrine aging of the female brain and the associated decline in synaptic plasticity during endocrine aging. In the perimenopausal rodent model, two distinct aging programs were identified: endocrine and chronological. Endocrine aging refers to changes that were coincident with changes in rat cycling phenotype independent of chronological age, as age was held constant at 9-to 10-month-old for comparison between regular, irregular, and acyclic groups. In contrast, chronological aging refers to those changes that occurred in animals at different ages but the same cycling status (e.g., regular 6 months vs. regular 9-to 10-month-old; acyclic 9-to 10-monthold vs. acyclic 16 months).
The PAM in this study is a physiologically-relevant rodent model of the human perimenopausal transition thatdfrom an endocrine perspectivedrecapitulates key aspects of perimenopausal physiology: the 6-month-old regular cyclers correspond to STRAW stage 4 of regular cycles and peak fecundability; the 9-to 10-month-old irregular cyclers with prolonged cycles correspond to STRAW stage 3b of declining fecundability with increased cycle irregularity; 9-to 10-month-old acyclic may correspond to STRAW Stage 2 with increased anovulatory cycles, both hypoestrogenic and hyperestrogenic; and the 16-month-old acyclic rodents correspond to postmenopausal STRAW stage 0 (Finch, 2014) . Similar to humans, the PAM exhibited individual variability in both age of onset and rate of perimenopausal transition.
With respect to the number of statistical tests performed, the potential for false positives is of concern. To avoid interpretation system level responses based on a single indicator, we interrogated system level functions across multiple domains including peripheral and neural steroid hormone concentration in tandem with their cognate receptors, gene expression, protein expression, FDG-PET whole brain glucose metabolism, peripheral glucose tolerance, mitochondrial function, and LTP (synaptic plasticity). The consistency of systems level indicators across multiple systems/ platforms support our conclusions and allay concerns regarding false positive findings.
The perimenopausal transition was associated with complex profiles in steroid levels in brain and serum. How the perimenopausal transition affects brain levels of steroid hormones in human and rodents is poorly understood, although decreased brain estrogens are associated with AD in postmenopausal women (Rosario et al., 2011) and in an AD mouse model (Yue et al., 2005) . Recent evidence indicates good agreement between plasma and brain levels of E2 and P4 across the ovarian cycle in young female rats, although higher than expected brain levels suggest significant brain neurosteroidogenesis (Kato et al., 2013) . However, the data herein indicate that correlations evident in young animals do not generalize to the brain in transition as peripheral levels of steroids were not predictive of brain levels, particularly for E2.
Of note, changes in ERb expression (Fig. 2H ) temporally correlated with those of the bioenergetic gene expression profile during perimenopause (Fig. 3B) ; these changes may be ascribed to nuclear and/or extra-nuclear (mitochondrial and mitochondria-associated endoplasmic reticulum) ERb localization (Alvarez-Delgado et al., 2010; Milner et al., 2005; Yang et al., 2004) . It is noteworthy that the ERb selective agonist, diarylpropionitrile, as well as an ERb targeting phytoSERM (selective ER modulator) formulation potentiates brain mitochondrial function Yao et al., 2013) . These data indicate a regulatory role of ERb in brain bioenergetics such that the endocrine-associated alterations in ERb expression may contribute to the changes in brain metabolism. Unaltered ERa level during perimenopause is consistent with previous reports that E2 treatment had minimal effect on ERa expression in the female brains (Adams et al., 2002; Naugle et al., 2014; Wang et al., 2010) .
Our hypothesis-driven gene array focused on 5 functional domains revealed perimenopausal transformations that occur in female brain aging. These functional domains were selected to test the hypothesis that the perimenopausal transition is composed of bioenergetic, redox, lipid, and inflammatory responses that could be predictive of AD pathology. Overall, the outcomes of the gene array analyses indicate that: (1) the transition from regular to irregular cycling exhibited profound changes in gene expression; (2) the bioenergetic category was the most affected cluster (Fig. 3B) ; and (3) the expression profiles of gene groups including redox, inflammation, and lipid metabolism genes are tightly correlated and appear to be independent of that of the bioenergetic genes (Fig. 3C) . The impact of endocrine aging can be sustained in vitro as evidenced by astrocytes cultured from irregular cycling rats exhibited impaired glial neurotrophic activity relative to same aged rats with regular cycles (Arimoto et al., 2013) .
The endocrine transition manifested by irregular cycling thus emerged as a critical period for bioenergetic function characterized by a significant decline in the expression of genes required for glucose metabolism and mitochondrial function.
Furthermore, analyses of the gene expression data defined the metabolic phenotypes of the perimenopausal transition. The sequence from 6-month-old regular cyclers to 9-to 10-month-old regular cyclers to 9-to 10-month-old irregular cyclers represents an interconnected system of responses toward decreased expression of bioenergetic genes; this is likely due to an additive effect of chronological aging (6-month-old to 9-to 10-month-old regular cyclers) and endocrine aging (9-to 10-month-old regular to irregular cyclers), in which the latter proceeded on the background of the former and together induced a significant decrease in gene expression. Of note, the similarities in the bioenergetic gene profiles of the 9-to 10-month-old irregular cyclers and 16-month-old acyclic rats are consistent with the pattern of gene expression observed in earlier studies of aged male rats, aged female nonhuman primates and of AD patients (Blalock et al., 2011 (Blalock et al., , 2004 Kadish et al., 2009 ). The reduced expression of glucose-dependent metabolic genes in female rats transitioning from 6-month-old regular to 9-month-old regular and irregular cycling stages was also seen in male rats starting at 3e6 months of age (Kadish et al., 2009; Rowe et al., 2007) . Second, the transition from 9-to 10-month-old irregular to 9-to 10-month-old acyclic indicated that the bioenergetic phenotype that characterized the irregular cyclers was stage-limited: the acyclic animals exhibited a recovery of components of mitochondria oxidative phosphorylation capacity and fatty acid metabolism to a level comparable to age-matched regular cyclers whereas other components of the same system such as glycolysis were not recovered. This switch to fatty acid and/or ketone metabolism is consistent with the upregulation of fatty acid metabolism genes shown in male rats at 9e12 months of age (Kadish et al., 2009) , although in male rats, the shift starts as early as 3e6 months and there was not a stage when both the glucose and fatty acid metabolic systems were downregulated as seen in irregular cycling females. Finally, the transition from 9-to 10-month-old acyclic to 16-month-old acyclic is a direct chronological aging effect that is independent of the endocrine status and resulted in an overall decline in genes involved in bioenergetics.
The endocrine transition from 9-to 10-month-old regular to irregular cyclers was associated with a decrease in inflammatory genes (nuclear factor of kappa light polypeptide gene enhancer in B-Cells 2, interleukin 1 receptor-like 1, and Erk1); these changes were confirmed at the protein level (Fig. 4) . It is intriguing that endocrine aging does not activate proinflammatory genes in hippocampus, although further investigation is warranted given that the inflammatory response is usually region-and cell-type-specific in the brain. Notably, an upregulation of genes involved in inflammatory and complement pathways from 6-month-old to 9-to 10-month-old regular cycling females was also observed in male Fischer 344 rats between 6 and 9 months of age (Kadish et al., 2009) ; the continued activation of inflammatory genes when male rats aged further to 12 months was only seen in the acyclic but not the irregular cycling female rats in our study.
Analysis of genes related to amyloid processing showed an early age-related increase in clusterin, a stress-induced chaperone linked to AD pathogenesis by numerous pathways (Yu and Tan, 2012) . In contrast, the perimenopausal transition is associated with a downregulation of thimet oligopeptidase 1 that protects against Ab toxicity (Pollio et al., 2008) , and more advanced chronological aging was marked by reduced expression of Ide. Although we did not observe significant changes in Ide expression across the different stages of endocrine aging, our prior work demonstrated that ovariectomy-induced hormone depletion lowers messenger RNA and protein levels of Ide, effects that are reversed by E2 treatment (Jayaraman et al., 2012; Zhao et al., 2011) .
Because endocrine and chronological aging coincide during middle age, we expect that these gene changes not only have additive downstream functional consequences but common upstream regulators. The insulin/IGF1 signaling was identified as the upstream pathway by both aging programs, as confirmed by the diminished activation of IRS-1 and Akt in irregular cyclers ( Fig. 4D  and E) . This is also consistent with previous studies showing impaired insulin/IGF1 signaling during brain aging and in AD animal models and patients (Craft et al., 2013; Sancheti et al., 2013; Yin et al., 2013) . The identification of the AMPK-PGC1a-nuclear respiratory factor-1 signaling/transcriptional pathwaydinvolved in regulation of mitochondrial biogenesisdwas confirmed by decreased AMPK activation in 9e10 irregular cyclers (Fig. 4H) , consistent with reports of AMPK inhibition in rodent aging and AD brains Pedros et al., 2014) .
The deficits in bioenergetic gene expression during endocrine aging were further corroborated by a panel of functional indicators, including diminished brain glucose uptake, decreased mitochondrial respiration and compromised bioenergetic enzyme activity (Figs. 4 and 5 ). This phenotype of bioenergetic decline is consistent with studies demonstrating that loss of estrogen regulation is associated with systematic deficits in brain metabolism, ranging from glucose uptake to aerobic glycolysis to mitochondrial function and morphology (Hara et al., 2014; Nilsen et al., 2007; Yao et al., 2009 Yao et al., , 2010 Yao et al., , 2012 . It was also shown that the decline in brain glucose uptake is associated with a decrease in neuronal glucose transporter GLUT3 (Fig. 4A ) as reported in a previous study on female brain aging (Ding et al., 2013) . Further, the estrogen-controlled glucose metabolism appears to be replaced by ketone body metabolism when the rats transitioned from irregular cycling to acyclic, as suggested by increased expression of fatty acid metabolismrelated gene (carnitine palmitoyltransferase 2) and mitochondriarelated genes (Atpaf2 and Esrra) but unaltered glycolytic genes. This could represent an adaptive response of the midlife brain to enhance fatty acid metabolism and to use ketone bodies as alternative substrates due to declined glucose metabolism (Kadish et al., 2009) ; the adaptive response was transient and lost with further chronological aging to 16 months.
The energy-dependent synaptic transmission is susceptible to mitochondria dysfunction (Cheng et al., 2010) , and the expression of genes required for synaptic function decreases in AD (Blalock et al., 2011) . Compromised LTP in the irregular cyclers (Fig. 6) can thus be correlated to the decline in glucose metabolism and mitochondrial function (Fig. 5) . Moreover, one of the major transcriptional pathways implicated in hippocampal LTP, the CREB-CRE transcriptional pathway, is coregulated by ERK and activated by E2 (Brinton, 2008 (Brinton, , 2009 Foy et al., 1999; Thomas and Huganir, 2004) . Therefore, the decreased activation (phosphorylation) of both ERK1/2 and CREB (Fig. 4) in the irregular cyclers can also contribute to the impairment of LTP. The deficit in LTP of irregular cyclers is consistent with previous findings that female Long-Evans rats with irregular cycling exhibited poorer cognitive performance compared with rats with regular cycles (Paris et al., 2011) . In rhesus monkeys, peri-and/or postmenopausal animals exhibited significant impairment in recognition memory which was paralleled by a decline in perforated synapses (Hara et al., 2012) . These changes were relative to premenopausal performance and synaptic morphology and were independent of chronological age (Hara et al., 2012) . Collectively, these data are consistent with the hypothesis that mechanisms underlying select cognitive functions are part of an endocrine aging program rather than a chronological aging process (Hara et al., 2012) .
Our preclinical findings are consistent with clinical observations that menopausal women exhibit decreased brain glucose uptake in the posterior cingulate and prefrontal cortex of the brain (Rasgon et al., 2005) . In humans, cognitive deficits during the perimenopausal transition are increasingly documented (Maki and Resnick, 2001 ) and interestingly, these deficits were found to be improved after the transition into menopause (Greendale et al., 2009) . These clinical findings are consistent with outcomes of gene and protein expression, metabolic function, and LTP, which indicate that cognitive deficits evident during the perimenopause (irregular cycling) are associated with the bioenergetic deficits in glucose transport and metabolism, whereas the recovery of cognitive function on menopause would be mechanistically linked to the utilization of ketone bodies as an adaptive and transitory response to impaired glucose metabolism. Bioenergetic deficits in the irregular cyclers were paralleled by systemic glucose intolerance, which confirmed earlier studies of the correlation between dysregulated peripheral metabolism (encompassing insulin resistance and dyslipidemia) and brain mitochondrial function (Blalock et al., 2010; Rettberg et al., 2014) . Consistent with these preclinical studies, findings from the Early versus Late Intervention Trial with Estradiol study indicate that a subgroup of menopausal women with dysregulated glucose metabolism exhibit poorer cognitive performance . Systemic glucose intolerance indicates an early stage of compromised insulin signaling, corroborating the bioinformatic prediction of decreased insulin/IGF-1 signaling at this stage. Together with clinical data documenting deficits in glucose metabolism in prodromal AD (Ewers et al., 2014; Mosconi, 2013; Protas et al., 2013) , our findings suggest that the bioenergetic transition of the perimenopause could have implications for development of a metabolic phenotype of risk for AD and may be relevant to the disproportionate burden of AD pathology in females and their 2-fold greater life time risk of AD (Alzheimer's Association, 2014; Barnes et al., 2005) . Although these data do not directly address the contributions of the perimenopause transition to the development of AD, they provide important and novel insights into understanding an early bioenergetic transition in brain that is associated with profile of risk. Specifically, these data indicate that endocrine aging is not a linear trajectory of overall decline but a selective adaptive systems biology response that results in a shift in the bioenergetic system of the brain that includes substrate utilization and mitochondrial function. This bioenergetic phenotype is reminiscent of early stage of AD and suggest that bioenergetic changes that occur early in the female aging brain contributes to an increased risk for AD in women. Collectively, these findings suggest a critical window for earliest detection of bioenergetic vulnerability of brain for later-life development of AD in those most affected, postmenopausal women.
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